Business
BELLUS HEALTH DELIVERING ON KEY STRATEGIC PARTNERSHIPS AND KIACTA(tm) PHASE III DEVELOPMENT
May 11, 2011 (Canada NewsWire Group) -- Updates provided at Annual and Special Meeting of S...
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n May 11, 2011 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\nUpdates provided at Annual and Special Meeting of Shareholders \n\n\nLAVAL, QC, May 11 /CNW Telbec/ - BELLUS Health Inc. (TSX: BLU) ("BELLUS\n Health" or the "Company") held its Annual Meeting of Shareholders\n today. President and Chief Executive Officer Roberto Bellini provided\n shareholders with updates on the progress in implementing the Company's\n business plan, on the status of its products, including the clinical\n progress of KIACTA™, its lead drug candidate for AA amyloidosis, as\n well as on BELLUS Health's strategy to continue building value for\n shareholders.\n\n\n"Executing on the business plan that we presented to shareholders at the\n beginning of 2010 has been our focal point in the past year, and I am\n pleased to report that our efforts delivered results," said Roberto\n Bellini, President and Chief Executive Officer of BELLUS Health. "In\n implementing our plan, we entered into several important partnerships\n for our products, including a strategic partnership with Celtic\n Therapeutics for our lead drug candidate KIACTA™ and several\n distribution partnerships for VIVIMIND™. We also continued to develop\n the products in our pipeline, particularly KIACTA™ which began its\n confirmatory phase III clinical trial in December, 2010. We also put in\n place a leaner organizational structure which is better adapted to our\n business mode...